---
figid: PMC9623415__fendo-13-1010092-g002
figtitle: PKC-mediated phosphorylation and activation of the MEK/ERK pathway as a
  mechanism of acquired trastuzumab resistance in HER2-positive breast cancer
organisms:
- Mus musculus
- Rattus norvegicus
- Cerobasis alpha
- Homo sapiens
organisms_ner:
- Rattus norvegicus
- Mus musculus
- Homo sapiens
- Danio rerio
pmcid: PMC9623415
filename: fendo-13-1010092-g002.jpg
figlink: /pmc/articles/PMC9623415/figure/f2/
number: F2
caption: 'Pathways involved in JIMT-1 trastuzumab resistance (log2 FC normalized to
  SKBR3 signals). AFISimilarly expressed protein: light grey; antibody not available/poor
  performance: no fill; overexpressed total protein ≥ 1.5-fold (log2 FC ≥ 0.58): light
  orange; ≥ 2-fold: *; under-expressed total protein ≤0.67 (log2 FC ≤ -0.58): light
  green; ≤ 0.5-fold: *; overexpressed phosphosite ≥ 1.5-fold: orange; ≥ 2-fold: *;
  underexpressed phosphosite ≤ 0.67: green; ≤ 0.5-fold: *; predicted active protein:
  dark red outline; predicted inactive protein: dark blue outline.'
papertitle: PKC-mediated phosphorylation and activation of the MEK/ERK pathway as
  a mechanism of acquired trastuzumab resistance in HER2-positive breast cancer.
reftext: Jeanesse Scerri, et al. Front Endocrinol (Lausanne). 2022;13:1010092.
year: '2022'
doi: 10.3389/fendo.2022.1010092
journal_title: Frontiers in Endocrinology
journal_nlm_ta: Front Endocrinol (Lausanne)
publisher_name: Frontiers Media S.A.
keywords: acquired resistance | breast cancer | phospho-profile | PKC/MEK/ERK | signalosome
  | HER2 positive | patient stratification
automl_pathway: 0.9376025
figid_alias: PMC9623415__F2
figtype: Figure
redirect_from: /figures/PMC9623415__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9623415__fendo-13-1010092-g002.html
  '@type': Dataset
  description: 'Pathways involved in JIMT-1 trastuzumab resistance (log2 FC normalized
    to SKBR3 signals). AFISimilarly expressed protein: light grey; antibody not available/poor
    performance: no fill; overexpressed total protein ≥ 1.5-fold (log2 FC ≥ 0.58):
    light orange; ≥ 2-fold: *; under-expressed total protein ≤0.67 (log2 FC ≤ -0.58):
    light green; ≤ 0.5-fold: *; overexpressed phosphosite ≥ 1.5-fold: orange; ≥ 2-fold:
    *; underexpressed phosphosite ≤ 0.67: green; ≤ 0.5-fold: *; predicted active protein:
    dark red outline; predicted inactive protein: dark blue outline.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Mtor
  - Cdk4
  - Defb1
  - Kras
  - Cdkn1b
  - Tmed7
  - Pdk1
  - Akt1
  - Gsk3b
  - Ctnnb1
  - Pik3cg
  - Araf
  - Braf
  - Map2k1
  - Mapk3
  - Mapk1
  - Creb1
  - Rps6kb1
  - Erbb2
  - Cdkn1a
  - Nsg1
  - Tpt1
  - Tceal1
  - Dctn6
  - Psmd9
  - Pdpk1
  - Pik3r1
  - Pik3cb
  - ras
  - Hras
  - Rem1
  - Raf1
  - Map2k2
  - Rps6ka1
  - Rps6ka2
  - MTOR
  - RPS6KB1
  - RPS6KB2
  - CDK4
  - ERBB2
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - IFI27
  - PSMD9
  - ZNRD2
  - DCTN6
  - TMED7
  - H3P23
  - PDK1
  - PDPK1
  - AKT1
  - AKT2
  - AKT3
  - GSK3B
  - CTNNB1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - SMDT1
  - KRAS
  - HRAS
  - NRAS
  - ARAF
  - BRAF
  - RAF1
  - MAP2K1
  - MAP2K2
  - RPS6KA1
  - RPS6KA2
  - RPS6KA3
  - RPS6KA4
  - RPS6KA5
  - RPS6KA6
  - MAPK3
  - MAPK1
  - CREB1
  - mtor
  - cdk4
  - her2
  - cdkn1a
  - pdk1
  - akt1
  - gsk3ba
  - ctnnb1
  - rab1ab
  - araf
  - braf
  - si:dkey-222f8.3
  - raf1a
  - map2k1
  - map2k2a
  - mapk3
  - creb1a
  - DDDD
---
